The OVHIPEC-1 trial (NEJM 2018) established cytoreductive surgery with HIPEC as a meaningful improvement over cytoreduction alone for Stage III epithelial ovarian cancer at interval debulking. Five-year follow-up data has continued to support the survival benefit. The question that has emerged since is what comes next, specifically, whether sequential intraperitoneal interventions through the patient’s care pathway can produce additional benefit ...